A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
| 対象疾患 | Systemic Lupus Erythematosus |
|---|---|
| 相 | 第1/2相 |
| スポンサー | Daiichi Sankyo |
| ステータス | 完了 |
| 参加者数 | 26 名 |
| 介入（薬剤） | DS-7011a |
| 開始日 | 2023年6月7日 |
| 完了日 | 2025年4月1日 |
| 結果公開日 | 2026年5月28日 |
概要
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.
Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus Erythematosus
| DS-7011a | 11 Participants |
|---|---|
| Placebo | 4 Participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
- Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
- Reducing Disparities in Medication Adherence in SLE — Duke University
- Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health